newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027Phase 3 barzolvolimab cold urticaria and symptomatic